News headlines about ContraFect Corporation (NASDAQ:CFRX) have trended somewhat positive on Friday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ContraFect Corporation earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 47.8049711115681 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Separately, Maxim Group reissued a “hold” rating on shares of ContraFect Corporation in a research report on Thursday, May 25th.

ContraFect Corporation (NASDAQ CFRX) traded up 4.76% during trading on Friday, hitting $1.10. The stock had a trading volume of 27,918 shares. The company’s 50 day moving average is $1.25 and its 200-day moving average is $1.55. ContraFect Corporation has a 12 month low of $1.00 and a 12 month high of $3.28. The company’s market cap is $81.02 million.

ContraFect Corporation (NASDAQ:CFRX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.11. On average, equities research analysts predict that ContraFect Corporation will post ($0.43) earnings per share for the current year.

In related news, Director Sol J. Barer purchased 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 25th. The stock was purchased at an average price of $1.24 per share, with a total value of $49,600.00. Following the completion of the acquisition, the director now owns 815,933 shares in the company, valued at $1,011,756.92. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders purchased 50,800 shares of company stock valued at $62,992. Insiders own 9.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: “ContraFect Corporation (CFRX) Receives Daily News Impact Rating of 0.13” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at

About ContraFect Corporation

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Insider Buying and Selling by Quarter for ContraFect Corporation (NASDAQ:CFRX)

Receive News & Stock Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related stocks with our FREE daily email newsletter.